Product News: Test & Measuring Instruments, Laboratory and Research Supplies & Equipment, Electronic Components & Devices
PGS Array optimizes embryo screening for IVF.
Press Release Summary:
July 14, 2014 - Offering 8 arrays of 60,000 spots, CytoSure™ Embryo Screen Array supports high-resolution genome-wide aneuploidy and copy number detection in pre-implantation embryos. Microarray can screen up to 14 embryos on single slide, which is particularly useful in embryo banking. For optimal hybridization and maximum accuracy, probe design exactly mirrors only amplified DNA; regions of genome that have not been amplified are therefore not represented, minimizing possibility of misleading results.
Original Press Release
OGT Launches High-resolution, High-throughput PGS Array
Press release date: July 8, 2014
Confident genome-wide aneuploidy detection in 14 samples on a single array
Oxford, UK — Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced the launch of a new high-resolution, high-throughput pre-implantation genetic screening (PGS) microarray aimed at improving embryo screening for in vitro fertilisation (IVF). The CytoSure™ Embryo Screen Array offers eight arrays of 60,000 spots for high-resolution genome-wide aneuploidy and copy number detection in pre-implantation embryos. The microarray can screen up to 14 embryos on a single slide, which is particularly useful in embryo banking — a common procedure for advanced maternal age samples — enabling the confident identification of the best embryo for implantation.
The CytoSure Embryo Screen Array is sensitive enough to work with small amounts of amplified DNA from a single embryo cell. For optimal hybridisation and maximum accuracy, the probe design of the CytoSure array exactly mirrors only the amplified DNA; regions of the genome that have not been amplified are therefore not represented, minimising the possibility of misleading results. Oligonucleotide arrays, such as the CytoSure Embryo Screen Array, typically provide lower batch-to-batch variation than alternative bacterial artificial chromosome (BAC) arrays, enabling more reliable analysis. In addition, flexibility in design and content further enhances the ability of oligonucleotide arrays to meet future research requirements.
The CytoSure Embryo Screen Array has been research-validated by the team at the Center for Human Genetics, University Hospital Leuven, Belgium. In the lab of Professor Joris Vermeesch they found that “the CytoSure array offers a good alternative to FISH or BAC aCGH for the detection of aneuploidies and chromosomal imbalances in DNA amplified from single embryo cells”.
“With an estimated 250,000 PGS tests performed each year worldwide and growing at a rate of over 10% per annum,” said Dr Mike Evans, CEO, OGT, “we saw a clear and unmet need for our optimised, oligo-based aCGH CytoSure Embryo Screen array. It offers significant advances over alternative platforms, including the facility to analyse up to 14 samples on a single array. This new array continues our goal of helping potential parents maximise their chances of IVF success.”
For more information on the CytoSure Embryo Screen Array, please visit www.ogt.com.
For further information, please contact:
Oxford Gene Technology
Begbroke Science Park, Begbroke Hill, Woodstock Road
Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826
F: +44 (0) 1865 848684
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™, SureSeq™ and Genefficiency™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products and services deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.
For more information on the Company, please visit our website at www.ogt.com
CytoSure™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.